European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD

Attention Deficit Hyperactivity Disorder (ADHD) has historically been viewed as a childhood disorder that resolves during adolescence. However, current evidence indicates that in approximately two-thirds of cases, the condition persists into adulthood. Despite this, adult psychiatry across Europe often lacks the necessary diagnostic expertise, treatment facilities, and awareness to manage the condition effectively. This consensus statement, developed by the European Network Adult ADHD, aims to address this gap by providing evidence-based guidance for clinicians.

Adult ADHD often presents differently than in childhood. While hyperactive behavior like running and climbing is typical in children, adults may experience internal restlessness, an inability to relax, and over-talkativeness. Impulsivity in adults can manifest as poor financial decision-making or impulsive career changes, while inattention often leads to disorganization and poor executive function. Diagnostic assessment must involve a detailed developmental history, with experts recommending the use of collateral information from partners or relatives to validate self-reports. The paper argues that rigid age-of-onset criteria (e.g., symptoms before age 7) are often unreliable and that diagnostic thresholds should be adapted for developmental age, such as allowing for a lower symptom count when clear impairment is present in adulthood.

The consensus panel advocates for a multimodal treatment approach. Pharmacotherapy, specifically using stimulants like methylphenidate and dexamphetamine, is identified as the most effective first-line intervention. The paper notes that concerns regarding addiction potential in adults are largely unfounded when these medications are used correctly under clinical supervision, as they help regulate dopamine levels rather than causing the rapid surges associated with abuse. When stimulants are contraindicated or ineffective, non-stimulant alternatives like atomoxetine are suggested. Beyond medication, the panel emphasizes the role of adjunctive psychosocial treatments, such as psychoeducation and cognitive behavioral therapy (CBT), to help patients manage secondary impairments and improve life functioning.